#Norway #Oslo #Radspherin #Colorectal Cancer #Oncoinvent

Oncoinvent Reports Groundbreaking Results from Radspherin® Clinical Trial

Oncoinvent ASA, a pioneering biotechnology firm specializing in radiopharmaceuticals for solid tumors, has recently disclosed notable data from its ongoing Phase 1/2a trial aimed at tackling colorectal peritoneal metastases using Radspherin®. This innovative treatment is designed specifically for patients suffering from this aggressive form of cancer, which often poses significant challenges in clinical management and has a dismal prognosis.

The trial, aptly named RAD-18-002, involved a single-arm study with 47 participants, of whom 36 were administered Radspherin® through direct intraperitoneal injection. The dosage provided was 7 MBq, targeting microscopic cancerous cells remaining after surgical interventions. One of the central focuses of this study was peritoneal recurrence-free survival (pRFS), a critical factor since patients with peritoneal metastases typically experience a high rate of relapse following standard surgical treatments.

The results from this trial were eye-opening: only 27.8% of patients treated with Radspherin® experienced peritoneal disease recurrence at the 18-month mark. In contrast, historical data shows that 50% of patients undergoing conventional care see similar recurrences at this interval. Additionally, at this time point, 61.1% of participants had experienced any form of cancer recurrence, but a meager 22.7% of these instances arose from the peritoneum, indicating that Radspherin® might potentiate better disease control compared to existing modalities.

The favorable safety profile exhibited by Radspherin® further reinforces its potential as an effective treatment for this daunting disease. According to clinical observations, Radspherin® effectively targets the residual cancerous deposits left behind after surgery, aiming to eliminate these micro-metastases and prolong patient survival without incurring significant side effects typically associated with chemotherapy or radiation.

Dr. Stein Gunnar Larsen, a key investigator involved in the trial at Oslo University Hospital, expressed optimism regarding the findings, stating that such outcomes surpass expectations for this high-risk patient demographic. His enthusiasm is echoed by Prof. Dr. Wilhelm Graf from Uppsala University Hospital, who acknowledged the serious treatment challenges taken on by this study and pointed to the promising data and acceptable safety profile of Radspherin® as a pathway to improved patient outcomes.

Besides the revelations from the RAD-18-002 trial, Oncoinvent has also initiated a Phase 2 trial assessing Radspherin® for peritoneal carcinomatosis stemming from ovarian cancer. Encouraging feedback regarding the safety of the lead-in cohort was provided earlier this year, fostering optimism as patient recruitment continues in both European and U.S. institutions.

In summary, the results from Oncoinvent's trial signify a potential breakthrough in the treatment of colorectal peritoneal metastases, a condition that has long evaded effective management strategies. With the clinical community watching attentively, Oncoinvent continues to cement its status as a leader in the fight against aggressive cancers through innovative solutions like Radspherin®. The company emphasizes the importance of ongoing research and the necessity of collaboration among patients, healthcare professionals, and clinical teams to bring forth novel therapies that could transform standard treatment paradigms.

With the data from this trial in tow, Oncoinvent is more determined than ever to refine its offerings and provide hope to patients grappling with the harsh realities of cancer. This momentum not only marks a significant stride in their clinical journey but also instills hope for the advancement of oncological treatment methodologies as a whole.